Sandbox: malabsorption: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
!
!
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Peak age of onset
| colspan="7" |'''Clinical manifestation'''
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" |History
! colspan="4" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Lab findings
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Physical exam
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Additional findings
! colspan="4" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Lab findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause/Pathogenesis
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Additional findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Gold standard diagnosis
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause/Pathogenesis
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Gold standard diagnosis
|-
|-
!
!
! colspan="6" |Symptoms
!Signs
|-
!
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Diarrhea
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Fever
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Fever
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Abdominal pain
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Abdominal pain
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Diarrhea
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Weight loss
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Weight loss
!
|-
|-
!
!
! align="center" style="background:#4479BA; color: #FFFFFF;" |Watery
! align="center" style="background:#4479BA; color: #FFFFFF;" |Watery
!Bloody
! align="center" style="background:#4479BA; color: #FFFFFF;" |Fatty
! align="center" style="background:#4479BA; color: #FFFFFF;" |Fatty
!
! align="center" style="background:#4479BA; color: #FFFFFF;" |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hgb
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hgb
Line 30: Line 35:
!
!
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |40-60
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 63: Line 68:
!
!
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Childhood
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
Adult
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
Line 98: Line 102:
!
!
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Any age
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 125: Line 129:
!
!
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
| align="center" style="background:#F5F5F5;" | Young adults
(20th)
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 153: Line 156:
!
!
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Young adults
(20th)
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 189: Line 191:
!
!
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Childhood
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Adult
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 217: Line 218:
!
!
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |30-50
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 251: Line 252:
!
!
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |20-50
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 274: Line 275:
!
!
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | 30th
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 300: Line 301:
!
!
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
| align="center" style="background:#F5F5F5;" | Childhood Adult
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 323: Line 324:
!
!
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Infancy
Adult
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 352: Line 352:
!
!
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |50-70
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
Line 384: Line 384:
!
!
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Any age
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
Line 415: Line 415:
!
!
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Any age
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
Line 443: Line 443:
!
!
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |30-50
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 464: Line 464:
!
!
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | 50-60
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 482: Line 482:
!
!
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |50-60
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 500: Line 500:
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 517: Line 517:
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphoma]]
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 534: Line 534:
! align="center" style="background:#DCDCDC;" |[[Agammaglobulinemia]]
! align="center" style="background:#DCDCDC;" |[[Agammaglobulinemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 551: Line 551:
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 568: Line 568:
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 585: Line 585:
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 602: Line 602:
! align="center" style="background:#DCDCDC;" |[[Small intestinal bacterial overgrowth]]
! align="center" style="background:#DCDCDC;" |[[Small intestinal bacterial overgrowth]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 619: Line 619:
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 636: Line 636:
! align="center" style="background:#DCDCDC;" |[[HIV AIDS|HIV infection]]
! align="center" style="background:#DCDCDC;" |[[HIV AIDS|HIV infection]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 652: Line 652:
! align="center" style="background:#DCDCDC;" |[[Giardiasis]]
! align="center" style="background:#DCDCDC;" |[[Giardiasis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 668: Line 668:
! align="center" style="background:#DCDCDC;" |[[Strongyloidiasis]]
! align="center" style="background:#DCDCDC;" |[[Strongyloidiasis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 684: Line 684:
! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]
! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  

Revision as of 16:07, 29 November 2017

Abbreviations: WBC: White blood cells; Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A

Cause Clinical manifestation Lab findings Additional findings Cause/Pathogenesis Gold standard diagnosis
Symptoms Signs
Diarrhea Fever Abdominal pain Weight loss
Watery Bloody Fatty WBC Hgb Plt Other lab findings
Whipple's disease + + ± + + ↓/↑
Celiac disease ± ± - + + - -
  • IgA endomysial antibody
  • Anti-tissue transglutaminase antibody
  • Anti-gliadin antibody
  • IgA endomysial antibody
  • IgA tissue transglutaminase antibody
Tropical sprue + + + + + - -
  • Diagnosis of exclusion
Crohns disease + + + + +
  • Abnormal immune response to self antigens
Ulcerative colitis + + + + +
  • Hypoalbuminemia
  • Hypokalemia
  • Hypomagnesemia
  • Iron deficiency
  • Elevated ESR
  • Elevated CRP
  • Abnormal immune response to self antigens
Cystic fibrosis - + ± + + - -
  • Positive DNA analysis for CFTR
  • Evaluated nasal transepithelial potential difference (NPD)
VIPoma + + - + + - - -
  • Primary secretory tumor
  • Elevated VIP levels
  • Followed by imaging
Zollinger-Ellison syndrome + + - + + - -
  • Elevated basal or stimulated serum gastrin> 120 pg/mL
Eosinophilic gastroenteritis  + + - + + - -
Primary bile acid malabsorption + + - + + - -
Abetalipoproteinemia + + - + + - - -
Microscopic colitis + - - + + - -
Hyperthyroidism + - ± + + - - -
  • Elevated T4
  • Elevated T3
  • Decreased TSH
Lactose intolerance + - - + - - - -
Irritable bowel syndrome ± ± - ± - - - -
  • Diagnosis of exclusion
Chronic pancreatitis + + - + +
Cirrhosis + + + + +
Short bowel syndrome
Intestinal lymphoma
Agammaglobulinemia
Intestinal lymphangiectasia
Amyloidosis
Mastocytosis
Small intestinal bacterial overgrowth
Drug induced enteritis
Infection HIV infection
Giardiasis
Strongyloidiasis
Tuberculosis